Home › Castration-Resistant Prostatic Cancer › Pennsylvania › Pittsburgh
Castration-Resistant Prostatic Cancer clinical trials in Pittsburgh, PA
4 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 3
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
RecruitingPhase 3
- UPMC Cancer Centers, Pittsburgh
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RecruitingPhase 1/2
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Castration-Resistant Prostatic Cancer trials in other cities
- Los Angeles, CA8 studies
- New York City, NY7 studies
- Seattle, WA6 studies
- Houston, TX6 studies
- Boston, MA5 studies
- Philadelphia, PA4 studies
- Queens, NY4 studies
- Mountain View, CA3 studies
- Minneapolis, MN3 studies
- Baltimore, MD3 studies
- San Francisco, CA3 studies
- St. Louis, MO3 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Lung Cancer23 studies
- Prostate Cancer23 studies
- Stroke22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.